A New Culprit in Cancer Therapy’s Cardiac Toll
A recent study in Cell Discovery reveals a novel mechanism of resistance to PARP inhibitors in BRCA1-deficient epithelial ovarian cancer, with significant implications for cardiovascular risk. Researchers discovered that phosphorylated EZH2, a protein typically involved in gene regulation, translocates to the mitochondria in cancer cells. This mitochondrial shift promotes tumor survival against PARP inhibitor therapy, a cornerstone of treatment for cancers with BRCA mutations. The findings highlight a non-genomic role for EZH2 and identify a potential therapeutic target to overcome drug resistance in oncology.
Study Significance: For cardiology professionals, this research underscores the complex interplay between cancer therapeutics and cardiovascular health, particularly relevant for patients with pre-existing cardiac risk factors or those developing cancer therapy-related cardiac dysfunction. Understanding the specific molecular pathways that drive tumor resistance can inform the development of more targeted oncology drugs, potentially reducing the broad systemic toxicity that contributes to adverse cardiac remodeling and heart failure. This work emphasizes the need for integrated cardio-oncology strategies to manage the long-term cardiovascular sequelae in cancer survivors.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
